A recent South African study has revealed that an alternative first-line HIV treatment regimen, featuring doravirine and tenofovir disoproxil (TDF), could significantly limit excess weight gain compared to the more commonly used combination of dolutegravir and tenofovir alafenamide (TAF). This finding, presented as part of the AIDS 2026 conference discussions, offers a new perspective for managing HIV, particularly for individuals concerned about metabolic side effects.
The research indicates that while both regimens are effective in viral suppression, the choice of antiretroviral drugs can have a marked impact on patients' weight. Unexplained or excessive weight gain has become an increasing concern within the HIV-positive community globally, including Australia, due to its potential links with other health issues such as cardiovascular disease and diabetes.
The study compared outcomes in patients initiating HIV treatment. Those starting on the doravirine and TDF regimen experienced less weight gain over the study period than those on the dolutegravir and TAF combination. This differential in weight management could be a crucial factor in treatment selection, particularly for individuals with pre-existing risk factors for metabolic conditions or those who have experienced significant weight changes on previous therapies.
Dolutegravir and TAF have been widely adopted as first-line treatments in many countries, including Australia, owing to their high efficacy and generally good tolerability. However, the associated weight gain has been an emerging area of research and clinical discussion. The South African findings provide valuable data that could inform future treatment guidelines and personalised medicine approaches.
For Australian patients, these results underscore the importance of ongoing dialogue with their healthcare providers regarding treatment options and potential side effects. The availability of multiple effective regimens allows for tailored treatment plans that consider individual health profiles, lifestyle, and concerns, including body weight and metabolic health.
While the study was conducted in South Africa, its implications are relevant to the global HIV community, including Australia, where similar challenges regarding treatment-related weight gain are observed. Further research and real-world data collection will be essential to fully understand the long-term impacts and to integrate these findings into comprehensive patient care strategies.
